Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Apr 2015 09:05

RNS Number : 5893J
Venn Life Sciences Holdings PLC
08 April 2015
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Venn Life Sciences Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

X

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Henderson Global Investors

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

2 April 2015

6. Date on which issuer notified:

7 April 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

1,691,667

1,691,667

Below 5%

Below 5%

GB00B9275X97

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 5%

Below 5%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

This disclosure has been calculated based on issue share capital amount 39,227,632.

14. Contact name:

Scott Dickenson

15. Contact telephone number:

020 7818 4184

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAPLPEEASEEF
Date   Source Headline
30th Jan 201511:57 amRNSHolding(s) in Company
28th Jan 201512:05 pmRNSGrant of Options
6th Jan 20157:00 amRNSDirectorate Change
23rd Dec 20147:00 amRNSYear End Update
10th Dec 20147:00 amRNSInnovenn Board Appointment
20th Nov 20147:00 amRNSInnovenn commences production at new facilities
11th Nov 20147:00 amRNSEUR1.4m contract win with US firm
21st Oct 20147:00 amRNSEUR1.2m Contract with Global Pharmaceutical Comp
30th Sep 20147:01 amRNSStrategic Investment in InnoVenn
30th Sep 20147:00 amRNSInterim Results
18th Sep 201411:29 amRNSHolding(s) in Company
8th Sep 20143:00 pmRNSIssue of Consideration Shares
8th Sep 20147:00 amRNSEUR2.4m contract for pan-European coronary study
5th Aug 20147:00 amRNSAcquisition of French CRO
24th Jun 20143:44 pmRNSResult of AGM
24th Jun 20147:00 amRNSAGM Statement
19th Jun 20147:00 amRNSSkin science patent grant
27th May 20142:26 pmRNSDirector's Dealing
16th May 201412:25 pmRNSMajor contract win
16th May 201412:23 pmRNSFinal Results
2nd Apr 201412:21 pmRNSHolding(s) in Company
31st Mar 201411:48 amRNSResult of general meeting
18th Mar 20142:46 pmRNSUpdate on the Acquisition of Evocutis plc
14th Mar 20147:00 amRNSPlacing to raise £1 million & Notice of GM
13th Mar 20141:00 pmRNSUpdate of Evocutis plc acquisition
13th Mar 20141:00 pmRNSResult of AGM and General Meeting
26th Feb 20147:00 amRNSAcquisition of the trading assets of Evocutis PLC
26th Feb 20147:00 amRNSCirc re. Disposal and Notice of GM
13th Jan 20147:00 amRNSUpdate re: Aquisition of German based CRO
9th Dec 20137:00 amRNSAcquisition of Belfast Based CRO
29th Nov 201312:16 pmRNSHolding(s) in Company
31st Oct 20137:00 amRNSAcquisition
11th Oct 20131:31 pmRNSHolding(s) in Company
3rd Oct 201312:55 pmRNSDirector's Dealing
2nd Oct 20132:17 pmRNSChange of Registered Office
27th Sep 20137:00 amRNSInterim Results
23rd Jul 20133:39 pmRNSResult of AGM
13th Jun 20137:00 amRNSFinal Results
17th May 20137:00 amRNSInnovation division launch & co-development
7th May 20138:36 amRNSHolding(s) in Company
26th Apr 20137:09 amRNSProject wins
9th Apr 20137:00 amRNSSenior Management Appointments
14th Mar 20137:00 amRNSBoard Appointment
5th Mar 20131:19 pmRNSHolding(s) in Company
28th Feb 201312:47 pmRNSDirector/PDMR Shareholding
21st Feb 20139:49 amRNSDirector/PDMR Shareholding
7th Feb 20137:00 amRNSVenn Life Sciences expands into Russia
14th Dec 20127:00 amRNSAdmission to trading on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.